Am J Drug Alcohol Abuse. 1988;14 Suppl 1:1-69.
Benzodiazepines are medications used to treat many of the most frequent and disturbing symptoms seen in medical practice, including anxiety, insomnia, muscle spasms, some forms of epilepsy, and other illnesses. The World Health Organization (WHO) has determined benzodiazepines to be "essential drugs" that should be available in all countries for medical purposes. As benzodiazepines were recognized as generally safe and effective drugs, their medical use increased but so did problems of abuse outside medical practice. This report focuses specifically on the nonmedical use, or abuse, of benzodiazepines for purposes, durations, or at dosage levels not intended by the prescribing physician or in ways outside medical guidelines. The principal contribution of this report to the resolution of the controversy about the use of benzodiazepines is to draw a sharp distinction between the medical use of these drugs and their nonmedical use, which this report labels "abuse." Problems which exist with the medical use of benzodiazepines, such as their use by patients who are better treated with other medications (or without medication) and the problems of withdrawal symptoms on discontinuation of medically prescribed benzodiazepines, are not addressed because these are problems of routine, legitimate medical practice. On the other hand, aspects of medical practice which affect nonmedical use of benzodiazepines are extensively dealt with in this report including the diversion of legitimately prescribed benzodiazepines into the illicit drug market and the prescribing of benzodiazepines for drug abusers. Extensive animal and human research has shown that benzodiazepines are "reinforcing" drugs in the sense that animals and humans will maintain behavior on which delivery of the drug is dependent. Animal studies of self-administration of potentially abused drugs show that benzodiazepines are less powerful reinforcers than intermediate half-life barbiturates (such as secobarbital) and psychomotor stimulants (such as amphetamine and cocaine). A substantial body of human research has shown that benzodiazepines are moderately "liked" for their reinforcing effects by drug abusers and alcoholic subjects but that both anxious people and normal (non-drug abusing, non-anxious) human subjects prefer placebo to benzodiazepines, demonstrating that these substances are usually not liked by people who are not drug abusers or alcoholics. Among drug abusers, benzodiazepines are preferred less than either intermediate half-life barbiturates or stimulants. This difference between the response of substance abusers and normal and anxious research subjects supports the fundamental distinction
苯二氮䓬类药物是用于治疗医学实践中许多最常见且令人困扰的症状的药物,包括焦虑、失眠、肌肉痉挛、某些形式的癫痫以及其他疾病。世界卫生组织(WHO)已将苯二氮䓬类药物确定为“基本药物”,所有国家都应提供用于医疗目的。由于苯二氮䓬类药物被认为是普遍安全有效的药物,其医疗用途增加了,但医疗实践之外的滥用问题也随之增加。本报告专门关注苯二氮䓬类药物的非医疗用途,即滥用,包括用于超出开处方医生预期的目的、持续时间或剂量水平,或以超出医疗指南的方式使用。本报告对解决关于苯二氮䓬类药物使用的争议的主要贡献在于,明确区分了这些药物的医疗用途和非医疗用途(本报告将其称为“滥用”)。苯二氮䓬类药物医疗使用中存在的问题,例如对于使用其他药物(或不使用药物)治疗效果更好的患者使用该药物,以及停止按医嘱使用苯二氮䓬类药物时出现的戒断症状问题,本报告未涉及,因为这些是常规合法医疗实践中的问题。另一方面,本报告广泛探讨了影响苯二氮䓬类药物非医疗使用的医疗实践方面,包括将合法开具的苯二氮䓬类药物转入非法毒品市场以及为吸毒者开具苯二氮䓬类药物。广泛的动物和人体研究表明,从动物和人类会维持对药物递送有依赖性的行为这一意义上来说,苯二氮䓬类药物是“强化”药物。对潜在滥用药物自我给药的动物研究表明,苯二氮䓬类药物作为强化剂的效力低于中效半衰期巴比妥类药物(如司可巴比妥)和精神运动兴奋剂(如苯丙胺和可卡因)。大量人体研究表明,吸毒者和酗酒者因苯二氮䓬类药物的强化作用而对其有一定程度的“喜爱”,但焦虑人群和正常(不吸毒、不焦虑)人群更喜欢安慰剂而非苯二氮䓬类药物,这表明这些物质通常不被非吸毒者或酗酒者所喜爱。在吸毒者中,苯二氮䓬类药物的受青睐程度低于中效半衰期巴比妥类药物或兴奋剂。药物滥用者与正常及焦虑研究对象反应之间的这种差异支持了这一根本区别